BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37312399)

  • 21. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
    Wang H; Xu YC; Hsueh PR
    Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
    Cuervo G; Garcia-Vidal C; Puig-Asensio M; Vena A; Meije Y; Fernández-Ruiz M; González-Barberá E; Blanco-Vidal MJ; Manzur A; Cardozo C; Gudiol C; Montejo JM; Pemán J; Ayats J; Aguado JM; Muñoz P; Marco F; Almirante B; Carratalà J;
    Clin Infect Dis; 2017 May; 64(10):1374-1379. PubMed ID: 28329281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact on Antifungal Susceptibility Patterns of Previous vs. Revised Clinical and Laboratory Standards Institute Breakpoints for Candida Species Isolated from Candidemia: Experience of Two Tertiary Care Institutions in Japan.
    Hirano R; Minakawa S; Kitazawa J; Saito N; Kayaba H
    Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology and Outcomes of Non-albicans Candida Bloodstream Infections in Transplant Recipients and Cancer Patients.
    Otto C; Babady NE
    Mycopathologia; 2023 Dec; 188(6):863-871. PubMed ID: 37365379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes.
    Lai MY; Hsu JF; Chu SM; Wu IH; Huang HR; Lin CC; Lee IT; Chiang MC; Fu RH; Tsai MH
    Future Microbiol; 2017 Jun; 12():695-705. PubMed ID: 28326813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.
    Tadec L; Talarmin JP; Gastinne T; Bretonnière C; Miegeville M; Le Pape P; Morio F
    Mycoses; 2016 May; 59(5):296-303. PubMed ID: 26806101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology and antifungal susceptibility patterns of candidemia from a tertiary centre in Western Australia.
    Boan P; Gardam D
    J Chemother; 2019 May; 31(3):137-140. PubMed ID: 30955472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough fungemia due to Candida fermentati with fks1p mutation under micafungin treatment in a cord blood transplant recipient.
    Konuma T; Takahashi S; Kiyuna T; Miharu Y; Suzuki M; Shibata H; Kato S; Takahashi S; Tojo A
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27859978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
    Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
    Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.
    Taj-Aldeen SJ; Salah H; Perez WB; Almaslamani M; Motyl M; AbdulWahab A; Healey KR; Perlin DS
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features, antifungal susceptibility, and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-Taiwan.
    Tseng TY; Chen TC; Ho CM; Lin PC; Chou CH; Tsai CT; Wang JH; Chi CY; Ho MW
    J Microbiol Immunol Infect; 2018 Aug; 51(4):552-558. PubMed ID: 28625801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of fluconazole resistance and echinocandin tolerance in
    Daneshnia F; de Almeida Júnior JN; Arastehfar A; Lombardi L; Shor E; Moreno L; Verena Mendes A; Goreth Barberino M; Thomaz Yamamoto D; Butler G; Perlin DS; Colombo AL
    Emerg Microbes Infect; 2022 Dec; 11(1):2264-2274. PubMed ID: 36066554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
    Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
    Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
    Coste AT; Kritikos A; Li J; Khanna N; Goldenberger D; Garzoni C; Zehnder C; Boggian K; Neofytos D; Riat A; Bachmann D; Sanglard D; Lamoth F;
    Infection; 2020 Oct; 48(5):761-766. PubMed ID: 32661647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.
    Bizerra FC; Jimenez-Ortigosa C; Souza AC; Breda GL; Queiroz-Telles F; Perlin DS; Colombo AL
    Antimicrob Agents Chemother; 2014; 58(4):2438-40. PubMed ID: 24468776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.
    Jensen RH; Johansen HK; Søes LM; Lemming LE; Rosenvinge FS; Nielsen L; Olesen B; Kristensen L; Dzajic E; Astvad KM; Arendrup MC
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1500-8. PubMed ID: 26711776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Associated with Breakthrough Fungemia Caused by
    Kimura M; Asano-Mori Y; Sakoh T; Abe M; Ueno K; Hoshino Y; Nakamura S; Umeyama T; Yamagoe S; Miyazaki Y; Baba M; Okada C; Ogura S; Mitsuki T; Yamaguchi K; Yuasa M; Kaji D; Kageyama K; Nishida A; Taya Y; Ishiwata K; Takagi S; Yamamoto H; Yamamoto G; Uchida N; Wake A; Taniguchi S; Araoka H
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0208121. PubMed ID: 35041512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
    Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
    Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.
    Shah DN; Yau R; Weston J; Lasco TM; Salazar M; Palmer HR; Garey KW
    J Antimicrob Chemother; 2011 Sep; 66(9):2146-51. PubMed ID: 21700622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing epidemiology of candidemia in a medical center in middle Taiwan.
    Hii IM; Chang HL; Lin LC; Lee YL; Liu YM; Liu CE; Chen CH; Cheng YR; Chang CY
    J Microbiol Immunol Infect; 2015 Jun; 48(3):306-15. PubMed ID: 24113067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.